Funding
← Back to your selection

Euclidean Capital

Activity from announced rounds

Activity in this selectionOct 17, 2026 · Jul 20, 2026

Euclidean Capital is the investor identified in Circle Pharma’s issuer announcement and by transaction counsel for InduPro.

Recorded funding activity

Circle Pharma develops macrocycle medicines using computational and structure-based methods. The recorded history also includes Savvy Wealth’s operating tools and investment support for financial advisors. Multiple Savvy entries remain separate events pending their own event-level review.

Sources
Rounds participated in
5
Confirmed lead rounds
0
2 roles undisclosed
New companies
4
First participation on record · 1 follow-on
Funding in participating rounds
$399.5M
5 disclosed · full round size, not this investor’s share

By stage

Series C+3
Series A1
Series B1

By primary sector

Biotech3
Fintech2

By country

United States5

Rounds

5 in this selection
Savvy Wealth

Savvy Wealth gives independent financial advisors an operating platform that combines practice tools, investment support and AI-assisted client work.

$100MSeries C
Participant
Circle Pharma, Inc.

Circle Pharma discovers macrocycle medicines for cancer and other serious diseases using its MXMO platform, which combines computational, structure-based design with synthetic chemistry to create cell-permeable compounds against difficult protein targets. Its lead programs are investigational and at discovery or preclinical stages.

$92.5MSeries E
Participant
Savvy Wealth

Savvy Wealth gives independent financial advisors an operating platform that combines practice tools, investment support and AI-assisted client work.

$100MSeries C
Participant
Leal Therapeutics

Develops neuro-metabolic therapeutics for schizophrenia and ALS

$30MSeries A
Role not disclosed
InduPro

Develops proximity-guided antibody-drug conjugate therapeutics for cancer and autoimmune disease

$77MSeries B
Role not disclosed